Top Page
Opthea
(Sydney:OPT)
Opthea (OPT) vs. iShares MSCI Australia ETF (EWA)
Opthea Business Overview & Revenue Model
Opthea Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | Gross Profit |
| 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | EBIT |
| -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | EBITDA |
| -199.29M | -223.30M | -133.16M | -52.85M | -24.92M | Net Income Common Stockholders |
| -220.24M | -211.88M | -127.99M | -60.79M | -16.12M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 172.47M | 133.99M | 64.90M | 157.43M | 62.02M | Total Assets |
| 188.79M | 148.19M | 87.32M | 184.36M | 71.89M | Total Debt |
| 141.65M | 272.98K | 0.00 | 150.47K | 265.08K | Net Debt |
| -30.82M | -133.71M | -64.90M | -157.28M | -61.76M | Total Liabilities |
| 264.60M | 156.98M | 17.55M | 4.16M | 7.08M | Stockholders Equity |
| -75.81M | -8.79M | 69.77M | 180.20M | 64.81M |
| Cash Flow | Free Cash Flow | |||
| -161.05M | -179.34M | -98.39M | -61.08M | ― | Operating Cash Flow |
| -161.02M | -179.30M | -98.37M | -61.06M | -8.24M | Investing Cash Flow |
| -33.49K | -32.64K | -23.32K | 880.07K | 482.83K | Financing Cash Flow |
| 243.73M | 248.70M | 236.62K | 156.76M | 48.06M |
Opthea Technical Analysis
Opthea Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$203.27M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
53 Neutral | AU$768.03M | ― | -53.99% | ― | ― | -40.19% | |
53 Neutral | AU$666.70M | ― | -56.99% | ― | 10.76% | -195.89% | |
46 Neutral | AU$332.21M | ― | -524.68% | ― | 322.26% | -53.98% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% | ||
| $260.76M | ― | -31.16% | ― | ― | ― |
Opthea Corporate Events
Opthea Limited announced the cessation of Quinton Oswald as a director effective June 2, 2025. This change in the board may influence the company’s strategic direction, particularly in its ongoing development of treatments for eye diseases. Oswald held significant unquoted options, which may impact stakeholder interests and the company’s financial strategies moving forward.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
Opthea Limited has announced the cessation of Susan Orr as a director, effective June 2, 2025. This update, provided under listing rule 3.19A.3, includes details of her interests in unquoted options to purchase shares, which may have implications for the company’s governance and strategic direction.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
Opthea Limited announced the cessation of Julia Haller as a director of the company, effective June 2, 2025. This change in the board of directors could impact the company’s strategic direction and stakeholder interests, as Haller held significant unquoted options in the company, which could influence market perceptions and investor confidence.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
Opthea Limited announced the resignation of four directors following the failure of its Phase 3 trials to meet primary endpoints and a significant workforce reduction. The company is in negotiations with Development Funding Agreement investors to explore future options, amidst trading suspensions on ASX and Nasdaq due to financial uncertainties.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
Opthea Ltd has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders of the company’s voting securities. This change in holdings, involving several subsidiaries of JPMorgan, indicates a shift in the investment landscape for Opthea, potentially impacting its market dynamics and stakeholder interests.
Opthea announced the discontinuation of its wet AMD trials after the COAST and ShORE Phase III trials failed to meet primary endpoints, leading to a 65% reduction in staff. The company remains in discussions with its Development Funding Agreement investors to explore options for the future, amid uncertainties about its ability to continue as a going concern. Opthea’s cash balance decreased to $101.4 million by the end of March 2025, reflecting operational spending and trial advancements, while the company is in trading suspension.
Opthea Limited has announced a significant reduction in its workforce by approximately 65% following negative results from its Phase 3 clinical trials for OPT-302 in combination with Aflibercept and Ranibizumab. This decision aims to conserve cash, with estimated cash reserves of US$100M as of March 2025, amid ongoing negotiations with Development Funding Agreement investors. The workforce reduction is expected to save around US$1M monthly in employee costs, although it raises concerns about the company’s ability to continue as a going concern, with trading in its securities suspended until further clarity is provided.
Opthea Limited, a company listed on the Australian Securities Exchange (ASX), has had its securities suspended from quotation due to concerns over its financial condition. The ASX determined that Opthea’s financial status does not meet the requirements for continued quotation, resulting in a breach of Listing Rule 12.2. The suspension will remain in effect until Opthea complies with the necessary listing rules, impacting the company’s operations and market position.
Opthea Limited has announced the discontinuation of its Phase 3 trials, COAST and ShORe, for wet AMD after the trials did not meet their primary endpoints. The company is assessing the impact of these negative results on its Development Funding Agreement and its status as a going concern. Opthea’s financial stability is uncertain, with ongoing discussions with investors and a suspension of trading in its securities until further clarity is provided.
JPMorgan Chase & Co. and its affiliates have become a substantial holder in Opthea Limited, acquiring a 5.18% voting power through various securities transactions. This development signifies a significant investment by a major financial institution, potentially impacting Opthea’s market dynamics and signaling confidence in the company’s future prospects.
Opthea Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of March 20, 2025. This change involves various transactions related to securities lending and rehypothecation agreements, impacting the voting securities previously held by JPMorgan’s subsidiaries. The cessation of JPMorgan as a substantial holder may affect Opthea’s market dynamics and stakeholder interests, as it reflects a shift in the company’s shareholder composition.
Opthea Limited has requested a voluntary suspension of its securities from trading on the ASX pending the announcement of results from its Phase 3 COAST clinical trial. This suspension is intended to maintain market stability until the company can release the top line results, which are expected to have significant implications for its operations and market positioning.
Opthea Limited has requested a trading halt on its securities pending the announcement of the top line results from its Phase 3 COAST clinical trial, which combines OPT-302 with Aflibercept. This trading halt indicates the potential significance of the trial results, which could impact Opthea’s market position and stakeholder interests, as the outcomes may influence future operations and strategic decisions.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Opthea Limited, acquiring a 5.10% voting power through various securities lending and brokerage agreements. This acquisition signifies a strategic investment by a major financial institution, potentially impacting Opthea’s market position and signaling confidence in its future prospects, which could influence stakeholder perceptions and market dynamics.
Opthea Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The announcement involves the quotation of 896 ordinary fully paid securities, which were issued as a result of options being exercised or other convertible securities being converted. This development is part of Opthea’s ongoing efforts to enhance its financial flexibility and strengthen its market position in the biotechnology sector.
Opthea Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX). The company is issuing 956 fully paid ordinary shares, which could impact its financial structure and potentially influence investor sentiment. This move is part of Opthea’s strategic efforts to strengthen its capital base and support its ongoing research and development initiatives.